睿知中国医院研究地图
候选清单

正在招募淋巴瘤不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由江苏省人民医院(南医大一附院)牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方江苏省人民医院(南医大一附院)Jiangsu Province Hospital南京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07126678,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically confirmed diagnosis of grade I, II, or IIIa follicular lymphoma (FL), treatment-naïve, stage III-IV disease, and meeting treatment criteria (GELF criteria);

    入选标准第 5 条

  3. All patients of childbearing potential must agree to use effective contraception during the study and for 24 months after treatment cessation; women of childbearing potential must have a negative urine pregnancy test before treatment initiation.

    入选标准第 11 条

    Received lymphoma-directed therapy within 2 weeks prior to enrollment;

    排除标准第 2 条

  4. Liver function: AST (SGOT), ALT (SGPT) ≤2.5×ULN (without liver involvement) or ≤5×ULN (with liver involvement); total bilirubin (TBIL) ≤ULN; serum creatinine (CRE) ≤1.5×ULN;

    入选标准第 8 条

    Creatinine clearance ≥30 mL/min (calculated by Cockcroft-Gault formula);

    入选标准第 9 条

  5. Known active hepatitis C virus (HCV) infection; other acquired/congenital immunodeficiency disorders, including HIV infection;

    排除标准第 14 条

    Malignancies treated with curative intent and no evidence of disease for ≥5 years before enrollment;

    排除标准第 17 条

  6. Pregnant or breastfeeding women;

    排除标准第 21 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);日常活动能力;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07126678,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntary participation with signed informed consent;
  2. Age ≥18 years and ≤75 years, regardless of gender;
  3. Life expectancy ≥3 months;
  4. ECOG performance status 0-2; patients with ECOG 3 may be enrolled only if their decline in performance status is disease-related and the investigator judges they may benefit from treatment;
  5. Histologically confirmed diagnosis of grade I, II, or IIIa follicular lymphoma (FL), treatment-naïve, stage III-IV disease, and meeting treatment criteria (GELF criteria);
  6. Measurable and/or evaluable lymphoma lesions;
  7. Adequate bone marrow reserve: absolute neutrophil count (ANC) >1.0×10⁹/L or platelets >75×10⁹/L, unless cytopenia is deemed related to bone marrow infiltration by lymphoma and the investigator believes it may recover;
  8. Liver function: AST (SGOT), ALT (SGPT) ≤2.5×ULN (without liver involvement) or ≤5×ULN (with liver involvement); total bilirubin (TBIL) ≤ULN; serum creatinine (CRE) ≤1.5×ULN;
  9. Creatinine clearance ≥30 mL/min (calculated by Cockcroft-Gault formula);
  10. Ability to comply with study visit schedules and other protocol requirements;
  11. All patients of childbearing potential must agree to use effective contraception during the study and for 24 months after treatment cessation; women of childbearing potential must have a negative urine pregnancy test before treatment initiation.

排除标准:Exclusion Criteria:

  1. Grade IIIb FL or transformed FL;
  2. Received lymphoma-directed therapy within 2 weeks prior to enrollment;
  3. Any severe medical condition, including but not limited to:
  4. Poorly controlled hypertension (defined as failure to achieve control despite lifestyle modifications and treatment with at least 3 maximally tolerated antihypertensive drugs [including diuretics] for ≥4 weeks, or requiring ≥4 antihypertensive drugs for adequate control);
  5. Uncontrolled congestive heart failure (NYHA class 3 [moderate] or 4 [severe]) within 6 months prior to screening;
  6. Left ventricular ejection fraction (LVEF) <50%;
  7. Symptomatic coronary artery disease (e.g., chest pain, palpitations, fatigue) or requiring medication;
  8. Severe bradycardia (heart rate <40 bpm), hypotension, dizziness, or syncope; patients with arrhythmia history require cardiac evaluation;
  9. Active bacterial, viral, fungal, or other infections (except for nail fungal infections) or major infections within 2 weeks before the first dose of study drug;
  10. Moderate to severe liver disease (Child-Pugh B or C);
  11. Active bleeding within 2 months before screening or clinically significant bleeding tendency per investigator judgment;
  12. Pulmonary conditions impairing function (e.g., pulmonary fibrosis, drug-induced pneumonitis) deemed intolerable by the investigator;
  13. Any psychiatric or cognitive impairment that may compromise understanding of informed consent, protocol compliance, or study adherence;
  14. Known active hepatitis C virus (HCV) infection; other acquired/congenital immunodeficiency disorders, including HIV infection;
  15. Central nervous system (CNS) involvement by lymphoma;
  16. Diagnosis or treatment for malignancies other than lymphoma, except:
  17. Malignancies treated with curative intent and no evidence of disease for ≥5 years before enrollment;
  18. Adequately treated basal cell carcinoma (excluding melanoma) with no evidence of disease;
  19. Adequately treated cervical carcinoma in situ with no evidence of disease;
  20. Hypersensitivity to any study drug;
  21. Pregnant or breastfeeding women;
  22. History of stroke or intracranial hemorrhage within 6 months before enrollment;
  23. Requiring anticoagulation with warfarin or equivalent vitamin K antagonists;
  24. Requiring chronic use of strong CYP3A inhibitors;
  25. Administration of live attenuated vaccines within 4 weeks before study entry.

引自 ClinicalTrials.gov, NCT07126678, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07126678,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07126678